HUGO ID Detailed Result 7218


HUGO ID 7218
Symbol MPO
Name myeloperoxidase
#Occurrence 123
#Paper 1

 


PMID Match String Actual String Score Flanking text Edited by Edit
16014720MPOMPO7.1Here we show that myeloperoxidase (MPO), MPO a key oxidant-producing enzyme during inflammation is upregulated in the 
16014720MPOMPO7.1that ventral midbrain dopaminergic neurons of mutant mice deficient in MPO are more resistant to MPTP-induced cytotoxicity than their wild-type littermates 
16014720MPOMPO7.1Supporting the oxidative damaging role of MPO in this PD model are the demonstrations that MPO-specific biomarkers 
16014720MPOMPO-specific1.0of MPO in this PD model are the demonstrations that MPO-specific biomarkers 3-chlorotyrosine and hypochlorous acid-modified proteins increase in the brains 
16014720MPOMPO7.1This study demonstrates that MPO participates in the MPTP neurotoxic process and suggests that inhibitors 
16014720MPOMPO7.1in the MPTP neurotoxic process and suggests that inhibitors of MPO may provide a protective benefit in PD 
16014720MPOMPO7.1Conversely myeloperoxidase (MPO), MPO and not ONOO seems to promote O O '-dityrosine formation 
16014720MPOMPO7.1Moreover MPO can use the NO degradation product NO 2 to generate 
16014720MPOMPO7.1Vliet et al. 1997 and studies of mice deficient in MPO demonstrate that this enzyme is one of the major sources 
16014720MPOMPO7.1Thus these results raise the unanticipated possibility that MPO a heme enzyme expressed in abundance in a variety of 
16014720MPOMPO7.1Consistent with this hypothesis we show here not only that MPO is detected in affected brain areas of MPTP-injected mice and 
16014720MPOMPO7.1in glial cells but also that mutant mice deficient in MPO are more resistant to MPTP-induced dopaminergic neurotoxicity 
16014720MPOMPO7.1These findings indicate that MPO does participate in the MPTP neurotoxic process and suggest that 
16014720MPOMPO7.1in the MPTP neurotoxic process and suggest that inhibitors of MPO may provide protective benefit in PD 
16014720MPOMPO-deficient1.0C57BL 6J mice ( Charles River Laboratories Wilmington MA and MPO-deficient mice that had been backcrossed >10 times into the C57BL/6J 
16014720MPOMPO7.1previously (Wu Wu et al. 2003 beta-actin were as follows MPO 5'-AGGATAGGACTGGATTGCCTG-3' (forward) forward and 5'-GTGGTGATGCCAGTGTTGTCA-3' (reverse); reverse beta-actin 5'-CTTTGATGTCACGCACGATTTC-3' (forward) 
16014720MPOMPO7.1MPO isolation and activity 
16014720MPOMPO7.1The methods used to prepare brain samples and to measure MPO activity are slight modifications of those described previously by Daugherty 
16014720MPOMPO7.1centrifugation final supernatants were collected and used immediately to assess MPO activity by monitoring the oxidation of tetramethylbenzidine as described previously 
16014720MPOMPO7.1Mouse MPO glial fibrillary acidic protein beta 2 integrin MAC-1 (CD116/CD18), CD116 
16014720MPOMPO7.1mouse tissues the primary anti-MPO antibody was a rabbit anti-human MPO antibody (DakoCytomation, DakoCytomation Carpinteria CA used at 1 1000 for 
16014720MPOMPO-deficient1.0with UV detection ( = 295 nm in WT and MPO-deficient mice at 90 min after the last injection of 20 
16014720MPOMPO7.1MPO is induced in the mouse ventral midbrain during MPTP-induced dopaminergic 
16014720MPOMPO7.1To examine the possibility that MPO is a component of the inflammatory response seen in the 
16014720MPOMPO7.1et al. 1999 Wu et al. 2002 we first assessed MPO mRNA and protein content in the ventral midbrain (i.e., i.e. 
16014720MPOMPO7.1saline-injected control mice the ventral midbrain contained low levels of MPO mRNA and protein ( Fig 1 A-C 
16014720MPOMPO7.1In contrast in MPTP-injected mice ventral midbrain levels of both MPO mRNA and protein increased in a time-dependent manner ( Fig 
16014720MPOMPO7.1Ventral midbrain MPO mRNA and protein expression levels peaked at 1 and 2 
16014720MPOMPO7.1We next asked whether the observed changes in MPO ventral midbrain content in MPTP-injected animals paralleled an alteration of 
16014720MPOMPO7.1ventral midbrain content in MPTP-injected animals paralleled an alteration of MPO enzymatic activity by monitoring oxidation of tetramethylbenzidine 
16014720MPOMPO7.1Consistent with the protein data we found that ventral midbrain MPO activity also rose during MPTP neurotoxicity in a time-dependent manner 
16014720MPOMPO7.1In contrast in mutant mice deficient in MPO (MPO MPO n = 2 the ventral midbrain did not 
16014720MPOMPO7.1In contrast in mutant mice deficient in MPO (MPO MPO n = 2 the ventral midbrain did not show higher 
16014720MPOMPO7.1Unlike in the ventral midbrain levels of MPO mRNA proteins and catalytic activity in the cerebellum (brain brain 
16014720MPOMPO7.1However more unexpected was the finding that no MPO alteration could be detected in the striatum (where where dopaminergic 
16014720MPOMPO7.1administration as illustrated by the lack of change in striatal MPO activity saline 14.0 _amp_#177 4.1 ( n = 7 versus 
16014720MPOMPO7.1Thus both protein levels and activity of MPO increase in the MPTP mouse model of PD specifically in 
16014720MPOMPO7.1The present study shows that the level of MPO expression increases markedly in diseased SNpc from both mice exposed 
16014720MPOMPO7.1This work also demonstrates that changes of MPO protein content and enzymatic activity in MPTP-intoxicated mice parallel ( 
16014720MPOMPO7.1Moreover MPO is found primarily in SNpc-reactive astrocytes (Figs Figs 2 3 
16014720MPOMPO7.1to detect any of the well established cellular sources of MPO (neutrophils, neutrophils monocytes or macrophages (Hampton Hampton et al. 1998 
16014720MPOMPO7.1The presence of MPO in damaged SNpc thus appears to derive essentially from a 
16014720MPOMPO7.1other neurodegenerative diseases namely HD and ALS it appears that MPO upregulation in the brain is not pathognomonic of PD 
16014720MPOMPO7.1Instead we believe that the occurrence of MPO in diseased brains is likely indicative of a disease process 
16014720MPOMPO7.1are generally believed to be the only cellular sources of MPO 
16014720MPOMPO7.1However neuronal expression of MPO is also increased in Alzheimer's disease (Green Green et al. 
16014720MPOMPO7.1injections are associated with a time-dependent increase in ventral midbrain MPO mRNA ( A C protein expression ( B C and 
16014720MPOMPO7.1A C Immunochemical studies revealed no specific MPO immunoreactivity in the ventral midbrain of saline-injected control mice 
16014720MPOMPO7.1dense network of fibers and scattered cell bodies positive for MPO are seen at the level of the SNpc after MPTP 
16014720MPOMPO-positive1.0Black arrows in D show the MPO-positive cellular elements 
16014720MPOMPO-positive1.0E-H Confocal microscopy demonstrates that ventral midbrain MPO-positive structures ( E red are also GFAP positive ( F 
16014720MPOMPO-positive1.0J-L In contrast ventral midbrain MPO-positive structures ( I red are not MAC-1 positive ( J 
16014720MPOMPO7.1A B Ventral midbrain MPO tissue content is increased in postmortem tissue from PD patients 
16014720MPOMPO7.1C Positive control (purified purified MPO 
16014720MPOMPO7.1C Inventral midbrain sections MPO (blue) blue is not detected in control tissues neither in 
16014720MPOMPO7.1D Conversely MPO immunoreactivity (blue, blue small black arrow is found in GFAP-positive 
16014720MPOMPO7.1A-D Ablation of MPO in mutant mice attenuates MPTP-induced striatal TH fibers and SNpc 
16014720MPOMPO7.1saline-injected animals p _lt_ 0.05 compared with saline- and MPTP-injected MPO mice 
16014720MPOMPO-deficient1.0Striatal MPTP metabolism in MPO-deficient mice 
16014720MPOMPO7.1MPO is expressed in reactive astrocytes after MPTP injection 
16014720MPOMPO7.1To elucidate the cellular origin of MPO in the ventral midbrain of MPTP-treated mice immunohistochemical studies were 
16014720MPOMPO7.1In saline controls diffuse MPO immunoreactivity was seen in the neuropil ( Fig 2 A 
16014720MPOMPO7.1MPTP-treated mice 2 d after the last injection ventral midbrain MPO immunostaining was stronger especially at the level of the substantia 
16014720MPOMPO7.1This analysis confirmed that MPO colocalized with the astrocytic marker GFAP as shown by the 
16014720MPOMPO7.1Conversely no evidence of MPO expression in microglial cells could be documented by using the 
16014720MPOMPO7.1No noticeable cellular MPO immunoreactivity was observed in the striatum or cerebellum of either 
16014720MPOMPO7.1These results demonstrate that MPO is primarily expressed in ventral midbrain astrocytes during the demise 
16014720MPOMPO7.1Expression of MPO is increased in PD midbrain 
16014720MPOMPO7.1To determine whether the changes in MPO observed in the MPTP mouse model of PD were present 
16014720MPOMPO7.1of PD were present in the human condition we assessed MPO protein levels in postmortem ventral midbrain samples from sporadic PD 
16014720MPOMPO7.1Consistent with the mouse data PD samples had significantly higher MPO protein contents compared with controls ( Fig 3 A B 
16014720MPOMPO7.1Like in mice there was no significant difference in MPO to beta-actin ratios in the striatum (PD, PD 1.1 _amp_#177 
16014720MPOMPO7.1Histologically cellular MPO immunoreactivity was not detected in the control ventral midbrain parenchyma 
16014720MPOMPO7.1However MPO immunoreactivity was seen in ventral midbrain sections from PD patients 
16014720MPOMPO7.1The similarity of the MPO alterations between the MPTP mice and the PD postmortem specimens 
16014720MPOMPO7.1of using this experimental model to study the role of MPO in the PD neurodegenerative process 
16014720MPOMPO7.1neurodegenerative diseases we wondered whether increases in the expression of MPO within areas of neurodegeneration can be found in neurodegenerative disorders 
16014720MPOMPO7.1cortex from ALS patients did not exhibit higher GFAP or MPO values (data data not shown 
16014720MPOMPO7.10.1 p _lt_ 0.01 n = 3-4 as well as MPO to beta-actin ratios (HD, HD 0.8 _amp_#177 0.2 vs controls 
16014720MPOMPO7.1This suggests that brain MPO expression is not specific to PD but rather generic to 
16014720MPOMPO7.1MPO deficiency protects against MPTP-induced neurodegeneration 
16014720MPOMPO7.1MPTP on the nigrostriatal pathway of mutant mice deficient in MPO (MPO MPO and their WT littermates (MPO MPO 
16014720MPOMPO7.1the nigrostriatal pathway of mutant mice deficient in MPO (MPO MPO and their WT littermates (MPO MPO 
16014720MPOMPO7.1deficient in MPO (MPO MPO and their WT littermates (MPO MPO 
16014720MPOMPO7.1In saline-injected MPO and MPO mice stereological counts of SNpc dopaminergic neurons and 
16014720MPOMPO7.1In saline-injected MPO and MPO mice stereological counts of SNpc dopaminergic neurons and striatal TH-positive 
16014720MPOMPO7.1In MPTP-injected MPO mice there was a ~70% loss of SNpc TH-positive neurons 
16014720MPOMPO7.1In contrast in MPTP-injected MPO mice there was only ~50% loss of SNpc TH-positive neurons 
16014720MPOMPO7.1To examine whether MPO ablation protects not only against structural damage but also against 
16014720MPOMPO7.1acid in the striatum as well as locomotor activity between MPO and MPO mice after MPTP injections 
16014720MPOMPO7.1the striatum as well as locomotor activity between MPO and MPO mice after MPTP injections 
16014720MPOMPO7.1Contrasting with the protection afforded by the lack of MPO on the nigrostriatal dopaminergic neurons the loss of striatal dopamine 
16014720MPOMPO7.1in motor performance caused by MPTP were as severe in MPO as in MPO mice ( supplemental material available at www.jneurosci.org 
16014720MPOMPO7.1caused by MPTP were as severe in MPO as in MPO mice ( supplemental material available at www.jneurosci.org 
16014720MPOMPO7.1To ascertain that the resistance of MPO mice was not attributable to alterations in MPTP toxicokinetics we 
16014720MPOMPO7.1(a a measure of mitochondrial function did not differ between MPO mice and their WT littermates ( Table 1 
16014720MPOMPO7.1MPO damages ventral midbrain proteins 
16014720MPOMPO7.1MPO is the only known mammalian source of HOCl at plasma 
16014720MPOMPO7.13-chlorotyrosine a specific and stable biomarker of protein damage by MPO (Heinecke Heinecke et al. 1999 
16014720MPOMPO7.1In contrast in MPTP-treated MPO mice ( n = 3 ventral midbrain 3-chlorotyrosine was undetectable 
16014720MPOMPO7.1tissues therefore supports the hypothesis that reactive intermediates produced by MPO damage brain proteins in MPTP-intoxicated mice 
16014720MPOMPO-damaged1.5To localize MPO-damaged proteins tissue sections were immunostained with HOP-1 a mouse antibody 
16014720MPOMPO7.1was detected in the SNpc of saline-injected mice or MPTP-injected MPO mice (data data not shown 
16014720MPOMPO7.1and sometimes in PD did not show any alteration in MPO expression or enzymatic activity as illustrated in Figure 3 
16014720MPOMPO7.1After MPTP injections mutant mice deficient in MPO showed more spared SNpc dopaminergic neurons and striatal dopaminergic fibers 
16014720MPOMPO7.1We also found that the lack of MPO did not alter key aspects of MPTP toxicokinetics ( Table 
16014720MPOMPO7.1Together these findings indicate that MPO contributes to the pathogenic cascade of deleterious events responsible for 
16014720MPOMPO7.1Surprisingly although alterations in MPO protein and enzymatic activity were only detected in the ventral 
16014720MPOMPO7.1and fibers of nigrostriatal dopaminergic neurons were preserved in MPTP-injected MPO mice ( Fig 4 
16014720MPOMPO7.1The relative resistance of dopaminergic neurons to MPTP-induced neurotoxicity in MPO mice was however not accompanied by a preservation of striatal 
16014720MPOMPO7.1It is thus conceivable that although ablation of MPO attenuates the loss of TH protein (as as evidenced by 
16014720MPOMPO7.1Targeting MPO alone may thus suffice to provide observable structural but not 
16014720MPOMPO7.1combination of strategies capable of providing structural protection such as MPO inhibition with other strategies capable of protecting/stimulating protecting stimulating dopaminergic 
16014720MPOMPO7.1Therefore whether MPO inhibition in PD can succeed not only in slowing neuronal 
16014720MPOMPO7.1As to how MPO neurotoxic actions on dopaminergic neurons are mediated two distinct and 
16014720MPOMPO7.1First and foremost MPO is known for its production of cytotoxic reactive oxygen species 
16014720MPOMPO-derived1.0membrane proteins and lipids subjected to the deleterious effects of MPO-derived oxidants such as HOCl 
16014720MPOMPO7.1Also supporting the oxidative role of MPO in the MPTP model is our immunohistochemical demonstration of HOCl-modified 
16014720MPOMPO7.1Aside from this oxidative effect MPO can be secreted and bind CD11b/CD18 CD11b CD18 integrins to 
16014720MPOMPO7.1the case of neutrophils ligation of CD11b/CD18 CD11b CD18 by MPO stimulates signaling pathways implicated in the activation of these cells 
16014720MPOMPO7.1the MPTP model and in PD this cytokine-like effect of MPO may represent an additional mechanism by which dopaminergic neurons are 
16014720myeloperoxidasemyeloperoxidase1.0here we show that myeloperoxidase mpo a key oxidant producing enzyme during inflammation is upregulated in the ventral midbrain of human pd and mptp mice.  
16014720myeloperoxidasemyeloperoxidase1.0conversely myeloperoxidase mpo and not onoo seems to promote o o ' dityrosine formation in this model of pd pennathur et al. 1999 .